Advanced

Effects of formoterol (Oxis (R) Turbuhaler (R)) and ipratropium on exercise capacity in patients with COPD

Liesker, JJW; Van de Velde, V; Meysman, M; Vincken, W; Wollmer, Per LU ; Hansson, Lennart LU ; Kerstjens, HAM; Qvint, U and Pauwels, RA (2002) In Respiratory Medicine 96(8). p.559-566
Abstract
Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium... (More)
Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium significantly improved TTE, FEV1, FEF25-75%, FRC, IVC, RV and sGAW compared with placebo. A negative dose-response relationship was observed with formoterol. Ipratropium increased time to exhaustion more compared with formoterol, 18 mug, but not with formoterol, 4.5 and 9 mug. No changes in Borg score were found. There was no difference in the adverse event profile between treatments. In conclusion, I week of treatment with formoterol and ipratropium significantly improved exercise capacity and lung function compared with placebo. However, a negative dose-response relation for formoterol was unexpected and needs further investigation. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
exercise capacity, formoterol, COPD
in
Respiratory Medicine
volume
96
issue
8
pages
559 - 566
publisher
Elsevier
external identifiers
  • wos:000177437700002
  • pmid:12195835
  • scopus:0036694823
ISSN
1532-3064
DOI
10.1053/rmed.2001.1335
language
English
LU publication?
yes
id
019baa84-5f5b-461f-b901-d4c15d885e33 (old id 331250)
date added to LUP
2007-11-14 14:22:40
date last changed
2017-01-01 07:07:20
@article{019baa84-5f5b-461f-b901-d4c15d885e33,
  abstract     = {Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium significantly improved TTE, FEV1, FEF25-75%, FRC, IVC, RV and sGAW compared with placebo. A negative dose-response relationship was observed with formoterol. Ipratropium increased time to exhaustion more compared with formoterol, 18 mug, but not with formoterol, 4.5 and 9 mug. No changes in Borg score were found. There was no difference in the adverse event profile between treatments. In conclusion, I week of treatment with formoterol and ipratropium significantly improved exercise capacity and lung function compared with placebo. However, a negative dose-response relation for formoterol was unexpected and needs further investigation.},
  author       = {Liesker, JJW and Van de Velde, V and Meysman, M and Vincken, W and Wollmer, Per and Hansson, Lennart and Kerstjens, HAM and Qvint, U and Pauwels, RA},
  issn         = {1532-3064},
  keyword      = {exercise capacity,formoterol,COPD},
  language     = {eng},
  number       = {8},
  pages        = {559--566},
  publisher    = {Elsevier},
  series       = {Respiratory Medicine},
  title        = {Effects of formoterol (Oxis (R) Turbuhaler (R)) and ipratropium on exercise capacity in patients with COPD},
  url          = {http://dx.doi.org/10.1053/rmed.2001.1335},
  volume       = {96},
  year         = {2002},
}